Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

  • David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer
  • Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer
  • James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair